Potent competitive inhibitors of oncogenic Ras proteins include modified peptides and peptidomimetics such as 1 and 2, respectively. They prevent the attachment of these mutated proteins to the cell membrane and the resulting unregulated cell proliferation and malignant transformation. This opens new perspectives for the development of anticancer agents, since oncogenic forms of the ras genes, which encode these proteins, frequently occur in human cancer cells.
No takes yet. Share an insight, caveat, or question.
Rob M. J. Liskamp (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: